BRAF and central nervous system cancer: A patient with a BRAF V600E mutation in a high‐grade glioma originating from ganglioneuroma was treated with dabrafenib (a selective inhibitor of BRAF V600E) and TTFields after the failure of TMZ‐based therapy.